Targeted Medical Pharma Files SEC Form 15

Los Angeles – October 19, 2018 –  Targeted Medical Pharma a United States based medical nutrition and dietary supplement manufacturer, filed a Form 15 with the Securities and Exchange Commission. “After a detailed analysis and thoughtful deliberation of the advantages and disadvantages of being an SEC reporting company, the company’s board of directors and management concluded that the costs of reporting are too high and unreasonably burdensome on a company that is restructuring and rebuilding,” said interim Managing Director, Marcus Charuvastra. 

According to Mr. Charuvastra, “The preparation and filing of reports, retention of outside legal and accounting resources, in addition to the amount of management time spent on the documents along with the current volume of trading common stock do not justify being a SEC reporting company.” 

The Company will continue to file reports as required for trading common stock on the Pink Sheets. Questions regarding the company and common stock can be directed to info@tmedpharma.com.    

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. (TRGM) a publicly traded, United States based medical nutrition company that develops amino acid based medical foods and other oral nutrition products for the long term management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep, respiratory disorders, allergies and cognitive disorders.

The Company manufactures 8 proprietary amino acid based medical foods along with the dietary supplements Grotrexa (Japan), AppTrim (Japan), Hypertensa Advanced and Clearwayz. Each product uses Targeted Cellular Technology, the Company’s patented micro-nutrient delivery system that improves the absorption and cellular utilization of amino acids, nutrients and neurotransmitters. The products are manufactured in the United States and sold directly to physicians, pharmacies and patients in the United States, Japan, New Zealand, Ukraine, Russia and China.

Forward Looking Statement 

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

####

Targeted Medical Pharma Finalizes Exclusive Agreement for Distribution in CHINA

Los AngelesTargeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product licensing agreement with Healthy Focus Limited, a Hong Kong based company that specializes in distributing healthcare products throughout China.

The Agreement grants Healthy Focus an exclusive three-year renewable license for the marketing and sale of Theramine®, Percura and Trepadone® in Hong Kong and China. Under the terms of the Agreement, Healthy Focus is responsible for registering all products in China, an initial licensing fee as well as maintaining annual minimum purchase orders of $500,000 for the first two years, and $1 million in the third year.

“We are excited to partner with Healthy Focus Limited to introduce our products to the Chinese Market,” said Kim Giffoni, Chief Executive Officer at Targeted Medical Pharma. “The execution of this agreement represents a significant expansion of international sales of our proprietary line of health products, and positions us for sustainable growth over the next three years.”

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and the dietary supplement for sinus and immune support, Clearwayz.  The products are sold directly to physicians, pharmacies, patients and hospitals in the United States and abroad.

 Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

####

Research Identifies a Potential New Path to Developing a Treatment for Chronic Pain

Los Angeles, September 8, 2015 – Targeted Medical Pharma to present new chronic pain research that reveals significant nervous system abnormalities among patients suffering from Fibromyalgia, at the 2015 PainWeek national conference in Las Vegas, Nevada.

The study looked at 329 Fibromyalgia patients and 58 control patients all of whom wore Holter monitors for a 24 hour period to measure nervous system activity. The results of this study showed that patients with Fibromyalgia experience a significant decrease in both nighttime parasympathetic nervous system (PNS) activity and daytime sympathetic nervous system (ANS) activity.

“Patients with Fibromyalgia often suffer from irritable bowel syndrome (IBS), sleep disorders, widespread pain, anxiety and fatigue,” said David Silver M.D. Chief Medical Officer at Targeted Medical Pharma, Board Certified Rheumatologist and former Director of the Cedars Sinai Chronic Pain and Rehabilitation Program. “Understanding that these symptoms can be attributed to a significant decrease in nighttime parasympathetic activity and an overall reduction in autonomic nervous system function in this patient population, will help guide the development of new therapies for Fibromyalgia and other chronic pain syndromes.”

The scientific poster (#115) titled: “Reduction in Parasympathetic Autonomic Nervous System Function in Fibromyalgia Patients,” will be presented by Dr. David Silver on September 10, 2015 at the Garcia Exhibit Hall, located in The Cosmopolitan Hotel in Las Vegas, Nevada.

About Medical Foods

Medical foods are amino acid based, FDA-regulated medications specially formulated to meet the distinct nutritional requirements of disease. Medical foods are specially formulated using ingredients that are Generally Recognized as Safe and are considered by many healthcare professionals to be a safe and effective alternative or adjunct to certain drug therapies for treating pain syndromes, sleep and cognitive disorders, hypertension and obesity without harmful side effects. Medical foods require the ongoing supervision of a physician or licensed healthcare professional. To learn more about medical foods please visit www.medicalfoods.com.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. (OTCQB:TRGM) is a Los Angeles based biotechnology company that specializes in the research, develop and commercialization of amino acid based medical foods for the management of pain syndromes, sleep and cognitive disorders, PTSD, obesity and hypertension. The company currently distributes amino acid based medical foods to healthcare providers, pharmacies and hospitals throughout the United States and abroad through a diverse network of sales channels.

####

New Research Finds a Link Between Obesity and Nutritional Deficiencies

Los Angeles, CA, April 27, 2015 — Obesity has reached epidemic proportions affecting nearly 78 million adults in the United States and has been linked with an increased risk of diabetes, heart disease, and cancer. Recent studies have suggested that obese patients have specific amino acid deficiencies that can contribute to obesity.

The latest research report entitled “Nutritional Deficiencies Associated with Obesity,” published online in the Journal of Obesity and Weight Loss Therapy, highlights the specific amino acid and nutrient deficiencies that are commonly associated with obesity. The report summarizes current research into the distinct nutritional deficiencies associated with Obesity and establishes the need for both continued research and treatments that are focused on addressing the unique micronutrient and metabolic needs of obese patients.

“Obesity is a major concern for healthcare providers as it increases the risk of certain disease states,” said Dr. David Silver, Chief Medical Officer at Targeted Medical Pharma Inc. and co-author of the report. “For over a decade, our Company has focused on developing amino acid based medical foods like AppTrim specifically designed to manage the distinct nutritional deficiencies associated with obesity.”

Research shows that amino acids and neurotransmitters help to regulate appetite, satiety and body weight, and that an imbalance in these substances can be a contributing factor to the problem of obesity. “Clinicians who are developing obesity management programs for their patients should take into account the specific amino acid and nutrient deficiencies that compromise an obese individuals ability to control appetite and food intake,” said Dr. Lynette Gebler, the principal author of the report. “Correcting the dietary deficiencies and establishing a targeted diet and exercise regimen in addition to a medical food like AppTrim may be very beneficial for obese patients.”

Twitter: @tmedpharma

Facebook: www.facebook.com/targetedmedicalpharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. (OTCQB:TRGM) is a biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.

####

Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan

Los Angeles, February 19,  2015 – Targeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product distribution agreement with J-Network Inc., a  California-based company that specializes in distributing cosmetic and healthcare goods exclusively to Japan.

The Agreement grants J-Network an exclusive one-year renewable license for the marketing and sales of the Company’s proprietary product, designed to improve sleep and immune function, in Japan. Under the terms of the Agreement, Targeted Medical Pharma will develop new products specific for import into the Japanese market, and J-network is responsible for a guaranteed initial order of 360,000 capsules as well as maintaining annual minimum purchase orders of 1.4 million capsules for the first two years, and 2.1 million capsules thereafter.

This is the second partnership between Targeted Medical Pharma and J-Network. From 2007 to 2011, the J-Network successfully marketed Targeted Medical Pharma’s products to a variety of consumer groups throughout Japan.

“The completion of this agreement represents managements renewed commitment to developing new revenue generating opportunities abroad,” said Kim Giffoni, Chief Executive at Targeted Medical Pharma. “J-Network is a reliable and honorable business partner who understands the value of our product line and has a successful track record of distributing our products in Japan.”

Connect with us on Google Plus, Linkedin, Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and the dietary supplement for sinus and immune support, Clearwayz™.  The products are sold directly to physicians, patients and pharmacies in the United States and abroad.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

####

Targeted Medical Pharma Announces Changes in Management and Board of Directors

New Management Structure Positions Company for Growth and Profitability

Los Angeles, CA, January 29, 2015 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced several major changes that streamline operations and signify a commitment to revenue growth, cost containment and profitability. The Company has appointed Kim Giffoni, a co-founder and former Vice President of Foreign Sales at Targeted Medical Pharma, as the Chief Executive Officer. Dr. David Silver, former Chief Operating Officer and President at the Company, has been appointed Chief Medical Officer, and Marcus Charuvastra, the Director of Marketing, takes over as Vice President of Operations and Marketing.

In addition, The Board of Directors has appointed veteran healthcare specialist Kerry Weems, as the new Chairman of the Board. Mr. Weems will be replacing Dr. William Shell, a co-founder and former Chief Executive Officer of the Company, who will remain a non-executive Director.  A nationally respected expert in health policy and government finance, Mr. Weems has served with distinction in the field of healthcare, including nearly 28 years in the Federal government, as Acting Administrator of the Centers for Medicare and Medicaid Services (CMS). Mr. Weems is currently Chief Executive Officer of TwinMed, a national medical supply distributor in Los Angeles.

“The new management structure will make Targeted Medical a leaner more efficient company adding a lot more value for our customers and shareholders,” said recently appointed CEO, Kim Giffoni. “The company can now focus on improving and expanding customer relationships as well as creating new business opportunities domestically and abroad.”

Twitter: @tmedpharma

Facebook: https://www.facebook.com/TargetedMedicalPharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops  medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness.  The company manufactures 10 proprietary medical foods, and the dietary supplement for sinus and immune support, Clearwayz™.  The products are sold directly to physicians, patients and pharmacies in the United States and abroad.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #

Targeted Medical Pharma, Inc. Announces Q3 Financial Results and Clinical Program Updates

Los Angeles, CA, November 18, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development biotechnology company, today announced financial results for its third quarter ended September 30, 2014 and clinical trial updates.

The company reported significant improvement in both net loss and net loss before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis.
In Addition, in Q3, the company reported major advances in the development of new treatments for both chronic low back pain and Posttraumatic Stress Disorder, publishing new data for the products Theramine, Sentra AM and Sentra PM in The American Journal of Therapeutics and The Journal of Central Nervous System Disease respectively.

Management Comments

William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma, commented, “The gains in net loss and EBITDA in Q3 reflect our steadfast commitment to cost containment and continued focus on developing profitable business verticals.” He continued, “We made a lot of progress in the third quarter of 2014 with our product development and clinical data programs. Two papers were published in peer reviewed journals further validating the efficacy of the medical foods Theramine, Senta AM and Sentra PM helping to position these products for wider adoption by clinicians and consumers.”

A copy of Targeted Medical Pharma’s quarterly report on Form 10-Q for the three months ended September 30, 2014, filed with the Securities and Exchange Commission on November 14, 2014, is accessible on the Company’s website at www.tmedpharma.com and at the SEC’s website at www.sec.gov.

Financial Overview

Quarter-over-Quarter Comparison:

Financial results for the three months ended September 30, 2014 compared to the three months ended September 30, 2013.

  • Total revenue of $1.7 million, a 24% decrease from $2.2 million during the three months ended September 30, 2013.
  • Total gross profit of $1.2 million, a 25% decrease from $1.6 million during the three months ended September 30, 2013.
  • Adjusted EBITDA of ($0.3) million, a 73% improvement from $(1.1) million during the three months ended September 30, 2013.

Net loss for the three months ended September 30, 2014, was $1.0 million compared to a net loss of $1.7 million for the three months ended September 30, 2013. The Company’s operating expense for the third quarter of 2014 was $1.9 million, a 39% decrease from the third quarter of 2013.


About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes medications for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

For Updates, Follow the Company on Twitter @tmedpharma or on Facebook at www.facebook.com/TargetedMedicalPharma.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. Forward-looking statements also include any other passages that relate to expected future events or trends that can only be evaluated by events or trends that will occur in the future. The forward-looking statements are based on the opinions and estimates of management at the time the statements were made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, among others, the risk of unforeseen changes in customer budgets, unanticipated loss of customers or delays in anticipated orders, the potential failure to attract new customers due to the company’s inability to competitively market its products and services, the risk of fluctuating demand for the company’s product, the potential failure to maintain desired customer relationships, costs and risks related to development of technologies. More information about factors that could cause actual results to differ materially from those predicted in Targeted Medical Pharma’s forward-looking statements is set out in its annual report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance upon these forward-looking statements, which speak only as to the date of this release. Except as required by law, Targeted Medical Pharma, undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

*Adjusted EBITDA refers to a financial measure that is more fully defined as net loss before net interest and other income, interest expense, income taxes, depreciation and amortization, and stock based compensation. Adjusted EBITDA is a non-GAAP financial measure which management believes reflects the Company’s ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in the Company’s business, as they exclude certain income or other expenses that are not reflective of ongoing operating results. Adjusted EBITDA is commonly used to analyze companies on the basis of leverage and liquidity. However, Adjusted EBITDA is not a measure determined under GAAP in the United States of America and may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA should not be construed as a substitute for net loss or as a better measure of liquidity than cash flow from operating activities, which are determined in accordance with GAAP. Management believes that Adjusted EBITDA is a useful measure for analyzing operating results, and uses this non-GAAP financial measure to review past results and forecast future results.

 

####

Targeted Medical Pharma Releases Promising Trial Results for the Treatment of Posttraumatic Stress Disorder

Study Shows Medical Foods Sentra AM and Sentra PM Effective at Reducing Symptoms of PTSD in Veterans

Los Angeles, CA, October  13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated with Posttraumatic Stress Disorder (PTSD).

In this 30 day open label pilot study (n=21), published in the Journal of Central Nervous System Disease, eligible subjects taking the medical foods Sentra AM and Sentra PM for thirty days showed a significant reduction in PTSD symptoms such as fatigue, cognitive dysfunction, sleep disturbances, anxiety, and panic attacks as measured by the PCL-M, and an average 57 percent increase in mental health scores as measured by the SF-36. “Clinically relevant improvements in sleep quality and a reduction in daytime drowsiness were also observed in this study, outcomes that are particularly relevant for treating PTSD successfully,” said Anthony Charuvastra, M.D. clinical assistant professor of child and adolescent psychiatry at NYU Langone Medical Center, and a specialist in PTSD.

The purpose of this pilot study was to examine the benefit of  unique nutritional interventions that focus on addressing specific amino acid deficiencies in patients with PTSD, that if corrected are capable of restoring balance to the autonomic nervous system and potentially alleviating many symptoms of the disease. The current treatment options for patients with PTSD are limited, associated with a variety of harmful side effects, and do not address the unique nutritional needs of the disease.

“The positive results of this small study indicate a need for a larger double-blind study and supports the hypothesis that treating the unique amino acid and nutrient requirements of PTSD with a medical food is a vital part of any treatment program aimed at reducing the impact of PTSD,” said William Shell, M.D. CEO and CSO of Targeted Medical Pharma, Inc.

Download the full publication here or click this link: http://bit.ly/medicalfoodsforptsd

Follow us on Twitter: @tmedpharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a publicly traded, Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.

The company also develops a line of dietary supplements designed to support health and wellness.  TMP currently manufactures 10 proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The Company is also developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #

Targeted Medical Pharma’s New Approach to Pain Management Targets Epidemic of Opioid and NSAID Over-Prescribing

White Paper explores Theramine® as a Safe and Clinically Effective Alternative to Common Pain Medications 

Los Angeles, CA, October 6, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine, as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation.

According to Consumer Reports, the overuse of opioid pain medications has reached epidemic proportions in the United States, and poses a significant public health problem. Roughly 45 people a day and more than 16,600 people a year, die from overdoses of these drugs, including methadonemorphine, andoxycodone (OxyContin) and hydrocodone combined with acetaminophen (Lortab and Vicodin). On September 30, 2014, the American Academy of Neurology published their new position regarding opioids, stating that the risks of opioids outweigh the benefits for headache, low back pain and other chronic conditions.

Theramine, a medical food specially formulated to address the increased amino acid requirements of pain syndromes, has been used clinically to manage back pain, migraines, Fibromyalgia and other pain syndromes since 2004 as an adjunct and replacement therapy to opioid, NSAID and anti-epileptic pain medications by physicians throughout the United States. Theramine, has been the subject of two double-blind clinical trials which are published in the American Journal of Therapeutics. In both studies, Theramine showed a statistically significant reduction in inflammation and improvement in low back pain than both naproxen and ibuprofen and proved to be effective at increasing specific amino acid levels in study subjects.

“The overprescribing of narcotic pain medications and the overuse of NSAIDs is a growing problem that our company and products can help address,” said William Shell M.D., CEO and Chief Science Officer at Targeted Medical Pharma. “Theramine is an effective clinical tool for physicians interested in managing pain and inflammation without the GI or cardiovascular side effects associated with NSAIDs or the addictive potential of narcotics.”

Twitter: @tmedpharma

Facebook: www.facebook.com/targetedmedicalpharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a publicly traded, Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.

The company also develops a line of dietary supplements designed to support health and wellness.  TMP currently manufactures 10 proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The Company is also developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #

Clinical Trial Results Confirm Amino Acid Based Medical Food Theramine® More Effective at Improving Chronic Back Pain than NSAID Pain Medications

Los Angeles, CA, September  23, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, announced the results of a second, double-blind clinical trial which confirmed that Theramine was shown not only to be more effective than ibuprofen in reducing low back pain, but also demonstrated a significant reduction in measures of inflammation.

In this 28 day, multi-center trial, subjects taking Theramine as either a standalone medication or in conjunction with a low dose ibuprofen, demonstrated a significant reduction in both low back pain and inflammation when compared to baseline and ibuprofen. Ibuprofen alone did not impact back pain and showed increased inflammation when compared to baseline.  The results of this study have been published online in the American Journal of Therapeuticsand can be viewed by visiting http://bit.ly/theraminehelpsbackpain.

“The overuse of NSAIDs is a growing concern among physicians and patients due to the potential stomach bleeding, heart attacks and strokes that are outlined on the black box warning associated with every NSAID product,” said William Shell M.D., cardiologist, CEO, and CSO at Targeted Medical Pharma. “The current recommendation of the American Geriatric Society is to restrict or eliminate the use of NSAIDs in patients 65 years of age and older due to their potential risks. The results of this and previous studies confirm that Theramine can be used as a safe and effective alternative to NSAIDs and potentially other dangerous pain medications for patients suffering from chronic pain.”

This trial examined the unique nutritional needs of patients with chronic back pain who at baseline showed reduced concentrations of the specific amino acids involved in reducing pain and inflammation. Subjects taking Theramine as a standalone medication showed significant improvements in plasma concentrations of these amino acids compared to baseline in addition to a reduction in pain and inflammation as measured by the Roland-Morris Pain Scale, Oswestry Disability Index, C-reactive protein (CRP) and Interleukin-6 (IL-6). Subjects taking ibuprofen alone showed no significant changes in these parameters. The results of this trial suggest that addressing the unique amino acid deficiencies associated with chronic pain using an amino acid based medical food can be significantly more effective at reducing pain and inflammation than NSAID therapies.

Twitter: @tmedpharma

Facebook: www.facebook.com/targetedmedicalpharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a publicly traded, Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.

The company also develops a line of dietary supplements designed to support health and wellness.  TMP currently manufactures 10 proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The Company is also developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #